Biocon
India’s National Task Force rejects Biocon’s itolizumab for COVID-19
July 27, 2020Sales and Marketing Biocon, COVID-19, India, Itolizumab
Biocon was hit with bad news over the weekend as the National Task Force for COVID-19 in its home country …
Mylan lands biosimilar sucker punch to Amgen’s blockbuster
June 6, 2018Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta
Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …
Top Ten most popular articles on Pharmafile.com this week
March 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten
Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for …
FDA inspection reveals cGMP issues at Biocon’s major Malaysia facility
March 13, 2018Manufacturing and Production Biocon, CGMP, FDA, pharma
Biocon’s insulin production facility in Johar, Malaysia – the largest integrated insulin manufacturing facility in Asia – has been slapped …
EMA committee recommends seven therapies from Roche, GSK, MSD and more
January 29, 2018Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Mylan and Biocon biosimilar approval expands to Brazil
January 2, 2018Manufacturing and Production, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, pharma, pharmaceutical
Since Mylan and Biocon managed to gain US FDA approval for its Herceptin (Trastuzumab) biosimilar, it has forged ahead in …
Mylan’s Ogivri becomes first and only FDA-approved Herceptin biosimilar
December 4, 2017Sales and Marketing Biocon, Cancer, FDA, Herceptin, Mylan, Roche, biosimilar, pharma
The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …
Mylan and Biocon Neulasta biosimilar knocked back by FDA
October 11, 2017Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical
Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …
FDA unanimously recommends Mylan and Biocon’s Herceptin biosimilar
July 14, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, healthcare, life sciences, pharma, pharmaceuticals
Mylan and Biocon have revealed that their biosimilar version of Roche and Genentech’s Herceptin (trastuzumab) has received unanimous recommendation from …
Problematic facility inspection puts Biocon’s biosimilar EU approvals on hold
July 10, 2017Manufacturing and Production, Sales and Marketing Biocon, India, biosimilars
Indian firm Biocon has been hit by regulator criticism which has forced its European biosimilar programme on hold following a …
Mylan and Biocon apply to FDA for biosimilar approval
January 12, 2017Sales and Marketing Biocon, FDA, Mylan, biosimilar, trastuzumab
Mylan, the US-based generics specialist, and Biocon, an Indian biopharmaceutical company, have applied for a biologics license application (BLA) for …
Major fire ravages Biocon subsidiary complex in India
December 13, 2016Manufacturing and Production Biocon, Syngene
A subsidiary of Indian biopharmaceutical firm Biocon was gutted by a major fire at Electronic City, Bangalore on 12 December, …
EMA accepts regulatory submission for proposed Herceptin biosimilar
August 26, 2016Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab
Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …
Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial
June 6, 2016Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab
Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
